Satoru Kakizaki

Takasaki, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 291 publications

Reply to "Did the COVID-19 pandemic disrupt the continuity of post-SVR surveillance in HCV-cured patients?"

Reply to "Did the COVID-19 pandemic disrupt the continuity of post-SVR surveillance in HCV-cured patients?"

Journal: Journal of gastroenterology

Published: August 17, 2026

Concurrent low skeletal muscle mass and fat area may predict poor survival in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab therapy.

Concurrent low skeletal muscle mass and fat area may predict poor survival in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab therapy.

Journal: Clinical nutrition ESPEN

Published: June 13, 2026

Simplified BALAD (BALAD-S) Score as a Guide for First-Line Immune Checkpoint Inhibitor Selection for Unresectable Hepatocellular Carcinoma.

Simplified BALAD (BALAD-S) Score as a Guide for First-Line Immune Checkpoint Inhibitor Selection for Unresectable Hepatocellular Carcinoma.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: May 29, 2026

Safety and Efficacy of Stereotactic Body Radiation Therapy in Very Elderly Patients (≥80 Years) with Solitary Hepatocellular Carcinoma.

Safety and Efficacy of Stereotactic Body Radiation Therapy in Very Elderly Patients (≥80 Years) with Solitary Hepatocellular Carcinoma.

Journal: Cancers

Published: May 05, 2026

Usefulness of the Lymphocyte-to-Monocyte Ratio in Predicting Prognosis in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab.

Usefulness of the Lymphocyte-to-Monocyte Ratio in Predicting Prognosis in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab.

Journal: Oncology

Published: April 19, 2026

Clinical outcomes of carbon-ion radiotherapy for residual or recurrent hepatocellular carcinoma after transarterial chemoembolization.

Clinical outcomes of carbon-ion radiotherapy for residual or recurrent hepatocellular carcinoma after transarterial chemoembolization.

Journal: ESMO gastrointestinal oncology

Published: April 17, 2026

Baseline DCP May Modify Response to Atezolizumab-Bevacizumab Versus Durvalumab-Tremelimumab in Unresectable HCC.

Baseline DCP May Modify Response to Atezolizumab-Bevacizumab Versus Durvalumab-Tremelimumab in Unresectable HCC.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: April 07, 2026

Real-world efficacy and safety of avatrombopag in Japanese patients with chronic liver disease and severe thrombocytopenia.

Real-world efficacy and safety of avatrombopag in Japanese patients with chronic liver disease and severe thrombocytopenia.

Journal: Journal of gastroenterology

Published: March 31, 2026

Identifying a biologically high-risk subgroup of anatomically resectable hepatocellular carcinoma.

Identifying a biologically high-risk subgroup of anatomically resectable hepatocellular carcinoma.

Journal: Hepatology international

Published: March 22, 2026

Peliosis Hepatis Induced by Tamoxifen Therapy in a Patient with Breast Cancer.

Peliosis Hepatis Induced by Tamoxifen Therapy in a Patient with Breast Cancer.

Journal: Internal medicine (Tokyo, Japan)

Published: March 18, 2026

Ablation-Based Salvage Strategy at Disease Progression After Initial Disease Control With Atezolizumab/Bevacizumab in Hepatocellular Carcinoma.

Ablation-Based Salvage Strategy at Disease Progression After Initial Disease Control With Atezolizumab/Bevacizumab in Hepatocellular Carcinoma.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: March 17, 2026

Successful retreatment with glecaprevir/pibrentasvir after sofosbuvir/velpatasvir failure in a patient with hepatitis C-related decompensated cirrhosis complicated by hepatocellular carcinoma.

Successful retreatment with glecaprevir/pibrentasvir after sofosbuvir/velpatasvir failure in a patient with hepatitis C-related decompensated cirrhosis complicated by hepatocellular carcinoma.

Journal: Clinical journal of gastroenterology

Published: February 25, 2026

Showing 1-12 of 291

Last Updated: 09/26/2026